Antibiotic-associated diarrhea: A refresher on causes and possible prevention with probiotics - Continuing education article

Journal of Pharmacy Practice

Volumn 26, Issue 5, 2013, Pages 476-482

  Varughese, Christy A ^a   Vakil, Niyati H ^b   Phillips, Kristy M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

adverse drug reaction; antibiotic associated diarrhea; Clostridium difficile; prevention; probiotics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BILE ACID; CARBAPENEM DERIVATIVE; CARBENICILLIN; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORTETRACYCLINE; ERTAPENEM; ERYTHROMYCIN; IMIPENEM; MEROPENEM; NEOMYCIN; NYSTATIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PROBIOTIC AGENT; TETRACYCLINE;

ACUTE PANCREATITIS; ANTIBIOTIC ASSOCIATED DIARRHEA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BIFIDOBACTERIUM BIFIDUM; BILE ACID METABOLISM; CANDIDA; CARBOHYDRATE METABOLISM; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CLOSTRIDIUM PERFRINGENS; DIARRHEA; DRUG SAFETY; FEBRILE NEUTROPENIA; HEMORRHAGIC COLITIS; HUMAN; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; RISK REDUCTION; SALMONELLA; STAPHYLOCOCCUS AUREUS;

ADVERSE DRUG REACTION; ANTIBIOTIC-ASSOCIATED DIARRHEA; CLOSTRIDIUM DIFFICILE; PREVENTION; PROBIOTICS;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBOHYDRATE METABOLISM; CLOSTRIDIUM DIFFICILE; COLON; DIARRHEA; DRUG MONITORING; HUMANS; MEDICATION ADHERENCE; PROBIOTICS;

EID: 84884693823     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190013499523     Document Type: Article

References (34)

1. Bartlett JG. Antibiotic-associated diarrhea. N Engl J Med. 2002 ; 346 (5). 334-339
2. Hogenauer C, Hammer HF, Krejs GJ, et al. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998 ; 27 (4). 702-710
3. Owens RC, Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for clostridium difficile infection. Clin Infect Dis. 2008 ; 46 (suppl 1). S19 - S31
4. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by saccharomyces boulardii: a prospective study. Gastroenterology. 1989 ; 96 (4). 981-988
5. Júnior MS. Recent changes in C. difficile infection. Einstein. 2012 ; 10 (1). 105-109
6. Cheng SH, Lu JJ, Young TG, et al. Clostridium difficile-associated diseases: comparison of symptomatic infection versus carriage on the basis of risk factors, toxin production, and genotyping results. Clin Infect Dis. 1997 ; 25 (1). 157-158
7. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. Dig Dis. 1998 ; 16 (5). 292-307
8. Borriello SP, Larson HE, Welch AR, et al. Enterotoxigenic clostridium perfringens: a possible cause of antibiotic-asoociated diarrhoea. Lancet. 1984 ; 1 (8372). 305-307
9. McDonald M, Ward P, Harvey K. Antibiotic-associated diarrhea and methicillin-resistant staphylococcus aureus. Med J Aust. 1982 ; 1 (11). 462-464
10. Holmberg SD, Osterholm MT, Senger KA, et al. Drug-resistant salmonella from animal fed antimicrobials. N Engl J Med. 1984 ; 311 (10). 617-622
11. Danna PL, Urban C, Bellin E, et al. Role of Candida in pathogenesis of antibiotic-associated diarrhoea in elderly inpatients. Lancet. 1991 ; 337 (8740). 511-514
12. Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated with diarrhea in an outpatient pediatric population. J Pediatr Gastroeneterology Nutr. 2003 ; 37 (1). 22-26
13. Schwaber J, Simhon Block C, et al. Factors associated with nosocomial diarrhea and clostridium difficile-associated disease on the adult wards of an urban tertiary care hospital. Eur J Clin Microbiol Infect Dis. 2000 ; 19 (1). 9-15
14. Toffler RB, Pingoud EG, Burrell MI. Acute colitis related to penicillin and penicillin-derivatives. Lancet. 1978 ; 2 (8092 pt 1). 707-709
15. Paul M, Yahav D, Bivas A, et al. Antipseudomonal beta-lactams for the initial, empirical treatment of febrile neutropenia: comparison of beta-lactams. Cochrane Database Syst Rev. 2010 ; 10 (11). CD005197
16. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007 ; 67 (7). 1027-1052
17. Dobbins WO, Herrero BA, Mansbach CM. Morphologic alterations associated with neomycin induced malabsorption. Am J Med Sci. 1968 ; 225: 63-77
18. Hove H, Tvede M, Brobech-Mortensen P. Antibiotic-associated dirrhoea, clostridium difficile, and short-chain fatty acids. Scan J Gastroenterol. 1996 ; 31 (7). 688-693
19. Sherman PM, Johnson-Henry KC, Yeung HP, et al. Probiotics reduce enterohemorrhagic escherichia coli O157: H7 and enteropathogenic E.coli O127: H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun. 2005 ; 73 (8). 5183-5188
20. Ogawa M, Shimizu K, Nomoto K, et al. Inhibition of in vitro growth of Shiga toxin-producing escherichia coli O157: H7 by probiotic lactobacillus strains due to production of lactic acid. Int J Food Microbiol. 2001 ; 68 (1-2). 135-140
21. Alvarez-Olmos MI, Oberhelman RA. Probiotic agents and infectious diseases: a modern perspective on a traditional therapy. Clin Infect Dis. 2001 ; 32 (11). 1567-1576
22. Doron S, Gorbach SL. Probiotics: their role in the treatment and prevention of disease. Expert Rev Anti Infect Ther. 2006 ; 4 (2). 261-275
23. Morrow LE, Gogineni V, Malesker MA. Probiotics in the intensive care unit. Nutr Clin Pract. 2012 ; 27 (2). 235-241
24. Castagliuolo I, Riegler MF, Valenick L, et al. Saccharomyces boulardii protease inhibits the effects of clostridium difficile toxins A and B in human colonic mucosa. Infect Immun. 1999 ; 67 (1). 302-307
25. Williams NT. Probiotics. Am J Health-Syst Pharm. 2010 ; 67 (6). 449-458
26. Salminen MK, Tynkkynen S, Rautelin H, et al. The efficacy and safety of probiotic lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials. 2004 ; 5 (4). 183-191
27. Snydman DR. The safety of Probiotics. CID. 2008 ; 46 (suppl 2). S104 - S111
28. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr. 2006 ; 83 (6). 1256-1264
29. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomized, double-blind, placebo controlled trial. Lancet. 2008 ; 371 (9613). 651-659
30. Videlock EJ, Cremonini F.. Meta-analysis: Probiotics in antibiotic-associated diarrhoea.. Aliment Pharmacol Ther. 2012 ; 35 (12). 1355-1369
31. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea. JAMA. 2012 ; 307 (18). 1959-1969
32. Cohen SH, Gerding DN, Johnson S, et al. Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical Practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of america (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010 ; 31 (5). 431-455
33. Johnston BC, Ma SSY, Goldengerg JZ, et al. Probiotics for the prevention of clostridium difficile-associated diarrhea: a systemic review and meta-analysis. Ann Intern Med. 2012 ; 157 (12). 878-888
34. Lactobacilli and bifidobacteria in the prevention of antibiotic- associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial [published online ahead of print August 8, 2013]. Lancet. :